Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03728166 · ClinicalTrials.gov registry record · NA

Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)

A NA study of Venous Thromboembolism, sponsored by Brigham and Women's Hospital.

Recruiting
Registry status
NA
Development phase
400
Enrollment target
1
Study location

NCT03728166 is a NA study of Venous Thromboembolism that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 400 participants, below the 6,287-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03728166, a NA study of Venous Thromboembolism, is actively recruiting participants, sponsored by Brigham and Women's Hospital.

RECRUITING
Registry status
NA
Development phase
400 participants
Enrollment target
1
Study location

Study Summary

Hospitalized medical patients have an increased risk of venous thromboembolism (VTE) across the continuum of care, including after hospital discharge. In the APEX Trial of hospitalized patients with acute medical illness, extended-duration post-discharge thromboprophylaxis with oral betrixaban reduced the frequency of asymptomatic proximal deep venous thrombosis (DVT), symptomatic proximal or distal DVT, symptomatic nonfatal pulmonary embolism (PE), or VTE-related death compared with short-duration enoxaparin. Obstacles to integration of these data in the hospitalized Medical Service patient population, including failure to identify at-risk patients, educational gaps in strategies for VTE prevention after discharge, and medication nonadherence, can be overcome with alert-based computerized decision support. This study is a single-center, 400-patient, randomized controlled trial of an EPIC Best Practice Advisory (BPA; alert-based computerized decision support tool) to increase prescription of extended-duration post-discharge thromboprophylaxis and decrease symptomatic VTE in high-risk patients hospitalized with medical illness. Specific Aim #1: To determine the impact of electronic alert-based CDS (EPIC Best Practice Advisory \[BPA\]) on prescription of extended-duration post-discharge thromboprophylaxis in high-risk patients hospitalized with medical illness who are not being prescribed any prophylactic anticoagulation for VTE prevention after discharge. Specific Aim #2: To estimate the impact of electronic alert-based CDS (EPIC BPA) on the frequency of symptomatic VTE in high-risk patients hospitalized with medical illness who are not being prescribed any prophylactic anticoagulation for VTE prevention after discharge.

Conditions Studied

Interventions

  • BEHAVIORAL Electronic alert

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2019-02-01
Est. Completion 2026-06-30
Phase NA

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT03728166

The ClinicalTrials.gov registry entry for NCT03728166 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,287-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (94% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Venous Thromboembolism appearing as the primary indexed condition, and to 1 intervention - of which Electronic alert is the first listed.

NCT03728166 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03728166 about?

NCT03728166 is a clinical study titled "Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)". Hospitalized medical patients have an increased risk of venous thromboembolism (VTE) across the continuum of care, including after hospital discharge. In the APEX Trial of hospitalized patients with acute medical illness, extended-duration post-discharge thromboprophylaxis with oral betrixaban reduc...

What is the current status of trial NCT03728166?

This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2019-02-01. Estimated completion is 2026-06-30.

What conditions does trial NCT03728166 study?

This clinical trial studies the following conditions: Venous Thromboembolism.

What interventions are being tested in trial NCT03728166?

The interventions under investigation include: Electronic alert (BEHAVIORAL).

Who is sponsoring clinical trial NCT03728166?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03728166 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Venous Thromboembolism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.